Business Context and Reporting Period
This Form 8-K is filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on November 10, 2016. The report serves to announce the company's financial results for the three and nine months ended September 30, 2016. The filing incorporates by reference a press release (Exhibit 99.1) detailing these results and announces a conference call held on the same date to discuss financial and operating outcomes.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is referenced but not included in the provided text.
Material Changes
The document does not explicitly list material changes versus prior periods. It only confirms that results for the three and nine months ended September 30, 2016, were announced and discussed in the referenced press release.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks.
- Risk Factors: Specific factors that could cause actual results to differ materially from anticipated results are referenced as being contained in the company's Form 10-K under the heading "Risk Factors."
- Outlook: No specific guidance or outlook figures are provided in this text; investors are directed to the press release and conference call for details on recent corporate developments.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) in the Exhibit 99.1 Press Release dated November 10, 2016, as they are not listed in this 8-K summary.
- Confirm the company name is OncoCyte Corporation, noting the discrepancy with the "Insight Molecular Diagnostics Inc." label in the request metadata.
- Review the Form 10-K for detailed risk factors referenced in the forward-looking statements disclaimer.
- Check for any subsequent filings or updates regarding the conference call discussed on November 10, 2016.